<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>CD25 (interluekin-2 receptor) expression in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>) cells has been not examined </plain></SENT>
<SENT sid="1" pm="."><plain>To characterize CD25(+) <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, 123 patients, who were newly diagnosed with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, were analyzed by single-color flow cytometry (FCM) </plain></SENT>
<SENT sid="2" pm="."><plain>CD25-positivity was significantly higher in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> patients (n = 123; mean ± SD, 27.8 ± 30.6%) than in those with reactive <z:hpo ids='HP_0002716'>lymphadenopathy</z:hpo> (n = 16; mean ± SD, 8.6 ± 4.3%) and follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 60; mean ± SD, 12.7 ± 12.4%) </plain></SENT>
<SENT sid="3" pm="."><plain>By two-color FCM, CD25/CD19 or CD25/CD20 dual positivity in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> patients was shown: mean ± SD, 63.7 ± 25.5% (n = 13) and 55.0 ± 28.1% (n = 14), respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Eighty-two percent of the patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> received rituximab combined with CHOP (<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi> and <z:chebi fb="0" ids="8382">prednisone</z:chebi>) chemotherapy </plain></SENT>
<SENT sid="5" pm="."><plain>A cut-off value of 60% with CD25-positivity clearly divided patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> into two groups: CD25-high or CD25-low <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Although clinical and immunophenotypic features were not significantly different in both groups, the former showed a significantly poorer response and more inferior progression-free survival than the latter </plain></SENT>
<SENT sid="7" pm="."><plain>CD25 may be a new prognostic marker and could be a therapeutic target in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> </plain></SENT>
</text></document>